<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Darier disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Darier disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Darier disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel Hohl, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H7872118">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Darier disease, also known as Darier-White disease, keratosis follicularis, or dyskeratosis follicularis (MIM #124200), is a rare autosomal dominant genodermatosis characterized by a persistent eruption of red-brown, keratotic papules scattered to confluent in a seborrheic distribution, nail abnormalities, pitting of palms and soles, and mucosal changes [
         <a href="#rid1">
          1
         </a>
         ]. The disease usually starts around puberty and runs a chronic course with exacerbations induced by sun exposure, heat, friction, or infections.
        </p>
        <p>
         This topic will discuss the pathogenesis, clinical features, diagnosis, and management of Darier disease. Other acantholytic skin disorders, including Hailey-Hailey disease and Grover disease, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15463.html" rel="external">
          "Hailey-Hailey disease (benign familial pemphigus)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5566.html" rel="external">
          "Grover's disease (transient and persistent acantholytic dermatosis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7872125">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Darier disease is a rare disorder that affects all ethnic groups. The estimated prevalence ranges from 1 to 4 per 100,000 people [
         <a href="#rid2">
          2-5
         </a>
         ]. In a Singaporean study, the incidence was 0.3 per 1 million people per year [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7872132">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the
         <em>
          ATP2A2
         </em>
         gene that encodes a sarco/endoplasmic reticulum Ca
         <sup>
          2+
         </sup>
         -adenosine triphosphate (ATP)ase pump (SERCA2) lead to both acantholysis and apoptosis, accounting for the characteristic pathologic finding of acantholytic dyskeratosis in Darier disease [
         <a href="#rid7">
          7
         </a>
         ]. SERCA2 actively transports calcium ions from the cytosol into the lumen of the endoplasmic reticulum to maintain a low cytoplasmic Ca
         <sup>
          2+
         </sup>
         level. Specific mutations of
         <em>
          SERCA2
         </em>
         induce defects in protein expression, ATP hydrolysis, calcium transport, and calcium binding and kinetics [
         <a href="#rid8">
          8
         </a>
         ].
         <em>
          SERCA2
         </em>
         mutations also have been associated with impaired synthesis, folding, or trafficking of desmosomal proteins and abnormal cytokeratin expression [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p>
         Despite its ubiquitous expression, the lack of compensatory SERCA3 expression in keratinocytes may explain their particular vulnerability to SERCA2 deficiency. SERCA2 haploinsufficiency has been proposed to underlie the dominant transmission pattern by affecting Ca
         <sup>
          2+
         </sup>
         -mediated maturation of cellular adhesion proteins and desmosomes in the endoplasmic reticulum through a stress response, resulting in decreased strength of intercellular adhesion [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         This mechanism has been used to develop a potential treatment. The glucosylceramide synthase inhibitor
         <a class="drug drug_general" data-topicid="10244" href="/z/d/drug information/10244.html" rel="external">
          miglustat
         </a>
         , a pharmacologic chaperone (small-molecule agents that enter cells and interact with mutant proteins allowing their correct folding and routing within the cell) used to treat mild to moderate Gaucher disease and Niemann-Pick type-C disease [
         <a href="#rid13">
          13
         </a>
         ], has been found to restore mature adhesion junctions and desmosomes and increase adhesion strength in Darier keratinocytes [
         <a href="#rid12">
          12
         </a>
         ]. This observation further supports the hypothesis of junctional adhesion protein misfolding as a pathogenetic mechanism in Darier disease. (See
         <a class="medical medical_review" href="/z/d/html/2934.html" rel="external">
          "Gaucher disease: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">
          "Overview of Niemann-Pick disease"
         </a>
         .)
        </p>
        <p>
         Alternatively, it has been proposed that mutant
         <em>
          ATP2A2
         </em>
         protein-insoluble aggregates that are not degraded by proteasomes induce endoplasmic reticulum stress and apoptosis, leading to acantholysis and dyskeratosis [
         <a href="#rid14">
          14
         </a>
         ]. However, this hypothesis is based upon in vitro studies using an immortal keratinocyte cell line with strongly overexpressed mutant SERCA2 pumps and may not apply to keratinocytes from Darier skin, which in most cases show a reduced expression of SERCA2 [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         Further pleiotropic faulty SERCA2-controlled Ca
         <sup>
          2+
         </sup>
         -dependent keratinocyte adhesion in Darier disease appears to be mediated by sphingolipid [
         <a href="#rid17">
          17
         </a>
         ] and protein kinase C (PKC)-alpha signaling [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31790782">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Darier disease is inherited in an autosomal dominant pattern, with complete penetrance and variable expressivity. Indeed, family history is often mistakenly dismissed due to its variable expressivity with clinical presentations too subtle to be recognized.
        </p>
        <p>
         Haploinsufficiency (where one copy of the wild-type gene is not able to prevent disease) is thought to be the mechanism for the autosomal dominant inheritance pattern, but aggregates of mutant SERCA2 (sarco/endoplasmic reticulum Ca
         <sup>
          2+
         </sup>
         -adenosine triphosphate [ATP]ase pump) were also proposed to exert a dominant negative effect. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         Nearly 300 familial and sporadic mutations in
         <em>
          ATP2A2
         </em>
         have been identified in patients with Darier disease, primarily missense mutations and frameshift mutations [
         <a href="#rid19">
          19,20
         </a>
         ]. The observation that family members with identical
         <em>
          ATP2A2
         </em>
         mutations may have significant differences in the clinical manifestations of the disease suggests that other genes or environmental factors affect disease expression [
         <a href="#rid21">
          21
         </a>
         ]. Along these lines, most studies could not identify robust genotype-phenotype correlations [
         <a href="#rid20">
          20
         </a>
         ]. However, the allelic acrokeratosis verruciformis of Hopf is caused by specific mutations in exon 14 encoding for the Ca
         <sup>
          2+
         </sup>
         -binding domain of SERCA2 [
         <a href="#rid22">
          22-25
         </a>
         ] and mutations in the S4-M4 region, with a severe neuropsychiatric phenotype of Darier disease [
         <a href="#rid26">
          26
         </a>
         ]. Whether other particular clinical subtypes, such as acral hemorrhagic or comedonal presentations, are due to specific mutations is more controversial [
         <a href="#rid20">
          20,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H49418038">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acantholysis and dyskeratosis are the main histologic features of Darier disease. Acantholysis is due to the loss of cell adhesion by desmosomes and detachment of keratin filaments from desmosomes, leading to characteristic rounding up of keratinocytes with suprabasal cleft formation. Dyskeratosis is a result of keratinocyte apoptosis and characterized by nuclear condensation and perinuclear keratin clumping.
        </p>
        <p>
         Two types of dyskeratotic cells are present in Darier disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Corps ronds" – Corp ronds are acantholytic, enlarged, round keratinocytes predominantly located in the stratum spinosum and stratum granulosum characterized by an irregular, eccentric, and sometimes pyknotic nucleus; a clear perinuclear halo; and encircled by a brightly eosinophilic ring of collapsed keratin bundles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Grains" – Grains are mostly located in the stratum corneum and consist of small, oval cells characterized by an intensely eosinophilic cytoplasm composed of collapsed keratin bundles and centered by elongated, shrunken, cigar-shaped nuclei.
        </p>
        <p>
        </p>
        <p>
         The epidermis with such acantholytic and dyskeratotic foci is thickened, contains large keratin plugs that fill the pilosebaceous follicles but are also found outside of follicles, and shows focal parakeratosis, papillomatosis, and hyperkeratosis. The underlying dermal papillae, covered by a single layer of epithelium (stratum basale), project into the clefts forming villus-like structures  (
         <a class="graphic graphic_picture graphicRef86189" href="/z/d/graphic/86189.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H7872139">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H49417901">
         <span class="h2">
          Skin lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In approximately 70 percent of patients, the initial lesions of Darier disease typically appear between the ages of 6 and 20 years and peak during the teenage years. The appearance is that of skin-colored or red-brown, keratotic, sometimes yellowish, crusted papules with a greasy, warty texture [
         <a href="#rid28">
          28
         </a>
         ]. The lesions typically involve the seborrheic areas (ie, forehead, scalp, notably the hairline, nasolabial folds, lateral aspects of the neck, presternal and interscapular areas) and may coalesce to form large, crusted, papillomatous masses  (
         <a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188" href="/z/d/graphic/70000.html" rel="external">
          picture 2A-E
         </a>
         ).
        </p>
        <p>
         Most patients also have mild involvement of the intertriginous areas (groin, axillae, and, in women, submammary fold). In a small subset of patients, flexural disease predominates with large, warty, vegetative plaques in the axillae, groin, or perineum. Flexural lesions may be disabling because of maceration and malodor.
        </p>
        <p>
         The hands are involved in most patients. Palmar lesions include punctate keratoses, pits, and, less frequently, hemorrhagic macules. In severe cases, palmoplantar hyperkeratosis may occur  (
         <a class="graphic graphic_picture graphicRef86185" href="/z/d/graphic/86185.html" rel="external">
          picture 3
         </a>
         ). Many patients have warty, flat-topped papules on the dorsa of the hands and feet. These are clinically indistinguishable from acrokeratosis verruciformis, an allelic autosomal dominant clinical subtype of Darier disease, which affects preferentially the dorsa of the hands and feet. (See
         <a class="local">
          'Acrokeratosis verruciformis of Hopf'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H49417908">
         <span class="h2">
          Nail changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Changes of the finger nails are present in most patients with Darier disease and provide an important diagnostic clue [
         <a href="#rid4">
          4,29
         </a>
         ]. White  (
         <a class="graphic graphic_picture graphicRef113564" href="/z/d/graphic/113564.html" rel="external">
          picture 4
         </a>
         ) and red longitudinal bands (ie, linear erythronychia)  (
         <a class="graphic graphic_picture graphicRef113565" href="/z/d/graphic/113565.html" rel="external">
          picture 5
         </a>
         ), longitudinal nail ridges and splitting, notching of the free nail border  (
         <a class="graphic graphic_picture graphicRef113566" href="/z/d/graphic/113566.html" rel="external">
          picture 6
         </a>
         ), and wedge-shaped subungual hyperkeratosis are common. A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding  (
         <a class="graphic graphic_picture graphicRef81865" href="/z/d/graphic/81865.html" rel="external">
          picture 7
         </a>
         ). Less commonly, these nail changes also occur on the toes. (See
         <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">
          "Overview of nail disorders", section on 'Darier disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H49417918">
         <span class="h2">
          Mucosal lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal lesions consisting of white papules with a central depression may be frequently seen in patients with Darier disease  (
         <a class="graphic graphic_picture graphicRef86184" href="/z/d/graphic/86184.html" rel="external">
          picture 8
         </a>
         ). These cobblestone lesions are found in the oral cavity and pharynx in approximately half of the cases but may also occur in the esophagus and on the anogenital mucosa [
         <a href="#rid30">
          30-33
         </a>
         ]. At times, oral lesions may cause blockage of the salivary ducts, particularly of the parotid gland, and xerostomia [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2325997156">
         <span class="h2">
          Ocular lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ocular lesions, particularly located on the anterior rim of the eyelid, are present in more than 50 percent of cases and are often associated with blepharitis, dry eye, and, very rarely, with corneal lesions [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H58289047">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with Darier disease complain of moderate itch, while intertriginous lesions may cause pain. Particularly distressing are malodor and appearance, which often lead to social isolation.
        </p>
        <p class="headingAnchor" id="H58289039">
         <span class="h1">
          CLINICAL VARIANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical variants of Darier disease include hypertrophic, verrucous, vesicobullous (dyshidrotic), erosive, and predominantly intertriginous forms. Segmental, acral hemorrhagic, and acrokeratosis verruciformis of Hopf are other distinctive variants of the disease [
         <a href="#rid20">
          20,27,36-39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H96302336">
         <span class="h2">
          Segmental variant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Linear or segmental forms of Darier disease may result from genetic mosaicism of
         <em>
          ATP2A2
         </em>
         [
         <a href="#rid40">
          40
         </a>
         ]. Type 1 mosaicism, reflecting a postzygotic somatic mutation in
         <em>
          ATP2A2
         </em>
         early during embryogenesis, presents with one or more unilateral bands of keratotic papules following the Blaschko lines [
         <a href="#rid41">
          41
         </a>
         ]. Type 2 mosaicism reflects a postzygotic mutation causing loss of heterozygosity at the
         <em>
          ATP2A2
         </em>
         locus and manifests with more severely affected linear bands of lesions superimposed on generalized disease [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H161132089">
         <span class="h2">
          Acral hemorrhagic variant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acral hemorrhagic Darier disease is an uncommon variant presenting with hemorrhagic macules, papules, or blisters located on the extremities, sometimes induced by trauma [
         <a href="#rid38">
          38,43-45
         </a>
         ]. This variant has been reported within families, but no specific genotype-phenotype correlation has been established.
        </p>
        <p class="headingAnchor" id="H1908421141">
         <span class="h2">
          Acrokeratosis verruciformis of Hopf
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acrokeratosis verruciformis of Hopf (AKV; MIM #101900) is an autosomal dominant allelic "forme fruste" of Darier disease, caused in most cases by a specific
         <em>
          ATP2A2
         </em>
         missense mutation [p.(Pro602Leu)] [
         <a href="#rid22">
          22,24,25
         </a>
         ]. In his original report, Hopf also described nail changes and palmoplantar pits in his patients.
        </p>
        <p>
         AKV is characterized by asymptomatic, skin-colored, flat-topped, wart-like papules on the dorsal aspects of the hands and feet and palmoplantar pits and punctate keratoses  (
         <a class="graphic graphic_picture graphicRef86092 graphicRef86093" href="/z/d/graphic/86092.html" rel="external">
          picture 9A-B
         </a>
         ). Histologically, AKV demonstrates undulating hyperkeratosis, papillomatosis, and hypergranulosis creating a "church spire" appearance, but acantholysis is generally absent  (
         <a class="graphic graphic_picture graphicRef113581" href="/z/d/graphic/113581.html" rel="external">
          picture 10
         </a>
         ), although the examination of serial sections from AKV lesions may show overlapping features with Darier disease [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Lesions of AKV are a common finding in patients with classic Darier disease. Warty lesions on the extremities may be an early manifestation of the disease, preceding the appearance of typical keratotic papules in a seborrheic distribution, particularly after intense sun exposure [
         <a href="#rid4">
          4,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H566775400">
         <span class="h1">
          ASSOCIATED CONDITIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1010338580">
         <span class="h2">
          Neuropsychiatric abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although neuropsychiatric abnormalities such as epilepsy, intellectual impairment, and mood disorders have been reported in association with Darier disease [
         <a href="#rid47">
          47-49
         </a>
         ], it is controversial whether particular mutations in
         <em>
          ATP2A2
         </em>
         or a closely linked susceptibility gene are associated with these disorders [
         <a href="#rid27">
          27,47,50,51
         </a>
         ]. Several studies support a pleiotropic effect of
         <em>
          ATP2A2
         </em>
         mutations on developmental delay and psychiatric morbidity in patients with Darier disease, but disfigurement and social isolation associated with severe skin disease are also contributing factors leading to depression and suicidal ideation [
         <a href="#rid48">
          48,52-54
         </a>
         ]. A higher frequency of
         <em>
          ATP2A2
         </em>
         gene-disrupting mutations have been found in patients with Darier disease and affective psychosis bipolar disorders or schizophrenia compared with those without neuropsychiatric disorders [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4046393187">
         <span class="h2">
          Type 1 diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A large, population-based study using data from the Swedish National Patient Register found that patients with Darier disease (n = 770) had a nearly twofold increased risk of type 1 diabetes compared with age-, sex-, and county of residence-matched individuals without Darier disease [
         <a href="#rid55">
          55
         </a>
         ]. These findings suggest that Darier disease may be a non-immunity-related risk factor for type 1 diabetes [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">
          "Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H49418100">
         <span class="h1">
          CLINICAL COURSE AND COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the severity of Darier disease is variable, the condition generally runs a chronic course with frequent exacerbations. Exacerbating factors include heat, sweat, sun exposure, friction, or infection [
         <a href="#rid28">
          28,57
         </a>
         ].
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         carbonate (commonly used to treat bipolar disorder) [
         <a href="#rid42">
          42,58
         </a>
         ], calcium channel blockers [
         <a href="#rid59">
          59
         </a>
         ], or interferon beta-1a [
         <a href="#rid60">
          60
         </a>
         ] can provoke flares of Darier disease and should be avoided.
        </p>
        <p>
         Bacterial, particularly staphylococcal, and fungal infections are frequent complications and can be severe or even fatal [
         <a href="#rid61">
          61
         </a>
         ]. The malodor of the skin lesions is a source of considerable distress for patients and may lead to social isolation.
        </p>
        <p>
         Widespread herpes simplex virus infection (eczema herpeticum, also known as Kaposi varicelliform eruption) and smallpox virus infection may rarely occur in patients with Darier disease [
         <a href="#rid62">
          62,63
         </a>
         ]. In a retrospective study of 79 patients with Darier disease, herpes simplex virus was detected in lesional skin in 11 patients (14 percent) [
         <a href="#rid64">
          64
         </a>
         ]. Eczema herpeticum is suspected if there is a sudden eruption of vesicular and crusted lesions with skin pain and fever. However, superinfection with herpes simplex virus may present as impetiginized erosions in the absence of vesicles or pustules [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Eczema herpeticum'
         </a>
         .)
        </p>
        <p>
         Ocular complications include warty, hyperkeratotic plaques with debris accumulation on the eyelid margin and chronic blepharitis  (
         <a class="graphic graphic_picture graphicRef113572" href="/z/d/graphic/113572.html" rel="external">
          picture 11
         </a>
         ) [
         <a href="#rid65">
          65
         </a>
         ]. Corneal ulcerations, recurrent herpetic keratitis, and staphylococcal endophthalmitis following cataract surgery have also been reported [
         <a href="#rid66">
          66-68
         </a>
         ].
        </p>
        <p>
         There are a few reports of squamous cell carcinomas arising in cutaneous or mucosal sites chronically affected by Darier disease [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7872153">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of skin-colored or yellow-brown, keratotic papules involving seborrheic areas such as forehead, hairline, nasolabial folds, ears, chest, and back  (
         <a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188" href="/z/d/graphic/70000.html" rel="external">
          picture 2A-E
         </a>
         ). Nail changes, including white and red longitudinal bands, a V-shaped nick at the free nail margin, and subungual hyperkeratosis, are an important diagnostic clue  (
         <a class="graphic graphic_picture graphicRef81865" href="/z/d/graphic/81865.html" rel="external">
          picture 7
         </a>
         ). A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         A skin biopsy for
         <strong>
         </strong>
         histologic examination is needed to confirm the diagnosis. The histologic diagnosis is based upon the finding of focal suprabasal acantholysis and dyskeratosis with characteristic eosinophilic "corps ronds" and "grains" in the epidermis and stratum corneum. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
         When bacterial or fungal superinfection is suspected, bacterial and fungal cultures of the involved sites are useful to determine appropriate antibiotic or antifungal treatment. In patients with vesicular lesions suggesting herpes virus superinfection (eczema herpeticum), a Tzanck smear and/or viral culture can confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Viral culture'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7872160">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of Darier disease may include severe seborrheic dermatitis, Hailey-Hailey disease, and Grover disease. However, Darier disease is readily distinguished by the clinical involvement of acral skin, nails, and oral mucosa:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seborrheic dermatitis
         </strong>
         – The skin lesions of seborrheic dermatitis are erythematous plaques with yellowish, greasy scales involving the scalp, eyebrows, nasolabial folds, or, occasionally, flexural areas such as axillae and groin  (
         <a class="graphic graphic_picture graphicRef59104 graphicRef68137 graphicRef53407" href="/z/d/graphic/59104.html" rel="external">
          picture 12A-C
         </a>
         ). Seborrheic dermatitis does not involve hands, feet, or nails, and there is no family history. Histology shows focal parakeratosis, psoriasiform acanthosis, and mild to moderate spongiosis; the complete absence of acantholytic dyskeratosis is a key criterion to differentiate seborrheic dermatitis from Darier disease. (See
         <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">
          "Seborrheic dermatitis in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hailey-Hailey disease (familial benign pemphigus)
         </strong>
         – Hailey-Hailey disease (HHD) primarily affects the intertriginous areas and may be difficult to differentiate from Darier disease with flexural involvement  (
         <a class="graphic graphic_picture graphicRef76004" href="/z/d/graphic/76004.html" rel="external">
          picture 13
         </a>
         ). Nail dystrophy is typically absent in HHD. Histology shows areas of partial suprabasal acantholysis with the characteristic appearance of a "dilapidated brick wall"  (
         <a class="graphic graphic_picture graphicRef75555" href="/z/d/graphic/75555.html" rel="external">
          picture 14
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/15463.html" rel="external">
          "Hailey-Hailey disease (benign familial pemphigus)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grover disease (transient and persistent acantholytic dermatosis)
         </strong>
         – Grover disease is an uncommon pruritic, papular, or papulovesicular rash that most commonly affects the trunk, but the papules are not confluent as in Darier disease  (
         <a class="graphic graphic_picture graphicRef76504" href="/z/d/graphic/76504.html" rel="external">
          picture 15
         </a>
         ). The face, oral cavity, palms, soles, or nails are not involved, and there is no family history. Histology shows subtle and focal acantholysis, with intraepidermal clefts and dyskeratotic cells  (
         <a class="graphic graphic_picture graphicRef56584" href="/z/d/graphic/56584.html" rel="external">
          picture 16
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5566.html" rel="external">
          "Grover's disease (transient and persistent acantholytic dermatosis)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7872169">
         <span class="h1">
          OVERVIEW OF TREATMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no cure for Darier disease. The goals of treatment are the improvement of skin appearance, relief of symptoms (eg, irritation, pruritus, or malodor), and prevention or treatment of infectious complications.
        </p>
        <p class="headingAnchor" id="H52210643">
         <span class="h2">
          Topical treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical therapies for Darier disease are aimed at controlling skin inflammation, reducing hyperkeratosis, and flattening the papular lesions. Topical treatments include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – Low- to medium-potency topical corticosteroids (groups 4 to 6  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) may reduce skin inflammation. Although their efficacy has not been evaluated in clinical trials, they are frequently used in patients with Darier disease on the basis of their anti-inflammatory properties and clinical experience.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical retinoids
         </strong>
         – Topical retinoids, including tretinoin 0.1% [
         <a href="#rid71">
          71
         </a>
         ],
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         0.1% [
         <a href="#rid72">
          72
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         0.05% [
         <a href="#rid73">
          73
         </a>
         ], have been used in patients with mild or localized disease to reduce hyperkeratosis and flatten papular lesions. As monotherapy, their efficacy has not been evaluated in clinical trials.
         <strong>
         </strong>
         Based upon clinical experience, topical retinoids are preferred to other topical agents, such as topical vitamin D analogues. Irritation is common and can be reduced by alternate-day application and liberal use of emollients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other topical agents
         </strong>
         – There are isolated reports of response to treatment with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid74">
          74
         </a>
         ],
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         [
         <a href="#rid75">
          75
         </a>
         ], tacalcitol [
         <a href="#rid76">
          76
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         sodium 3% gel [
         <a href="#rid77">
          77
         </a>
         ]. Several case reports suggest that topical fluorouracil (1 or 5%) may be particularly efficacious in combination with oral
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="local">
          'Systemic treatments'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H52210686">
         <span class="h2">
          Systemic treatments
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral retinoids
         </strong>
         – Oral retinoids, including
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         , etretinate, and
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         , decrease hyperkeratosis, smoothen papules, reduce odor, and produce significant clinical improvements in most patients with severe or generalized Darier disease. Etretinate is no longer available in the United States, Canada, and many other countries and has been replaced by acitretin. Oral alitretinoin is available in Europe and Canada but not in the United States. (See
         <a class="local">
          'Patients with severe or generalized disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of oral retinoids for the treatment of Darier disease has not been evaluated in randomized trials, and evidence is limited to small observational studies [
         <a href="#rid79">
          79-81
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a double-blind study including 26 patients with Darier disease treated with 30 mg per day of
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         or etretinate for four months, remission or marked improvement was achieved in 18 of 24 patients who took the drug for the duration of the study period, without difference between the two drugs [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          Alitretinoin
         </a>
         , a vitamin A analogue known to have anti-inflammatory and immunomodulating properties, has been successfully used in a few patients [
         <a href="#rid82">
          82,83
         </a>
         ] but may induce considerable adverse effects, including worsening of the skin lesions, pyogenic granuloma, erosions, and fever [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral retinoids do not induce prolonged remission in Darier disease, and long-term treatment is needed to prevent relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects of systemic retinoids include mucosal dryness, headache, delayed dark adaptation, diffuse hair loss (telogen effluvium), pyogenic granuloma, photosensitivity, hyperlipidemia, transaminase elevation, and skeletal hyperostosis. Oral retinoids are teratogenic, and appropriate counseling and contraception must be given to women of childbearing age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         <strong>
          treatments
         </strong>
         – In a small case series, low-dose
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         at 5 mg per day showed beneficial effects in moderate, but not severe, cases [
         <a href="#rid85">
          85
         </a>
         ]. In a single case report, low-dose intravenous immunoglobulins significantly reduced crusted lesions and itching [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H52210715">
         <span class="h2">
          Surgical or destructive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approaches for localized hypertrophic, erosive, or recalcitrant lesions that are resistant to conventional treatment include dermabrasion; electrosurgery; laser ablation; surgical excision; photodynamic or photon and electron beam therapy; and injection of botulinum toxin similar to the more established topical treatment targeting excessive sweating in Hailey-Hailey disease (benign chronic familial pemphigus; OMIM #169600) [
         <a href="#rid87">
          87-100
         </a>
         ]. Recurrence of lesions following excision and physical treatment is common.
        </p>
        <p class="headingAnchor" id="H1029842331">
         <span class="h1">
          APPROACH TO MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4143674646">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with Darier disease should be educated about simple measures to reduce the impact of exacerbating factors and control skin irritation. These measures include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keeping the skin cool and minimizing perspiration. Flares may be prevented by wearing lightweight cotton clothes, avoiding hot environments, and using sunscreens, especially during the summer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular use of moisturizers containing keratolytics such as topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         or lactic acid. Moisturizers reduce irritation, decrease scaling and hyperkeratosis, and improve the skin appearance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of antiseptic washes containing triclosan or
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         gluconate or bleach baths (one-fourth cup [60 mL] of household bleach in a full tub of water). Antiseptics reduce the burden of skin bacteria and odor. Patients may also be instructed to soak in astringents, such as
         <a class="drug drug_general" data-topicid="95641" href="/z/d/drug information/95641.html" rel="external">
          aluminum acetate
         </a>
         , if crusting is prominent or bacterial overgrowth is suspected.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17980225">
         <span class="h2">
          Patients with mild or localized disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild or localized disease, avoidance of triggers, regular use of emollients, and intermittent use of medium-potency topical corticosteroids (groups 4 and 5  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )), often combined with antibiotics (eg,
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">
          fusidic acid
         </a>
         ), are generally sufficient to control symptoms. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
         For patients with mild or localized disease that is not controlled by emollients and topical corticosteroids, we suggest topical retinoids. Tretinoin 0.05% or 0.1% cream,
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         0.1% cream, or
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         0.05% or 0.1% cream are applied to the involved skin once daily for three months.
        </p>
        <p>
         Because of the irritancy potential of topical retinoids, treatment is started with the lowest retinoid concentration applied on alternate days. After the first two weeks of treatment, frequency of application and retinoid concentration are gradually increased as tolerated. Emollients are used liberally in conjunction with topical retinoids. Intermittent use of medium-potency topical corticosteroids (groups 4 and 5  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) may reduce retinoid-induced irritation.
        </p>
        <p>
         Treatment with topical retinoids should not be started during pregnancy and should be discontinued in patients who become pregnant, although there is no direct evidence that topical retinoids cause congenital malformations [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17980233">
         <span class="h2">
          Patients with severe or generalized disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest oral retinoids such as
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         or
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         for patients with severe or extensive Darier disease. Treatment is generally started with a low dose (10 to 25 mg per day) to avoid initial exacerbation of the disease; the dose is then gradually increased as tolerated, up to 0.5 mg/kg per day for acitretin and 1 mg/kg per day for isotretinoin.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          Alitretinoin
         </a>
         is started at a dose of 10 mg per day and may be increased to 30 mg per day. Treatment should be continued for a minimum of three to four months to achieve reduction of hyperkeratosis, flattening of papular lesions, and reduction of malodor. Long-term treatment is needed to prevent relapse.
        </p>
        <p>
         Common side effects of systemic retinoids include mucosal and skin dryness, cheilitis, headache, delayed dark adaptation, diffuse hair loss, pyogenic granuloma, photosensitivity, hyperlipidemia, and elevation of liver transaminase levels. Long-term use induces skeletal hyperostosis on ligaments. Measurement of baseline serum lipid and liver enzyme levels is indicated before initiating
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         or
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         therapy. Monitoring of serum lipid and liver enzyme levels for the first two months and then every three months is adequate for patients on long-term retinoid therapy.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         are teratogenic. Appropriate counseling and contraception must be given to women of childbearing age before starting oral retinoids. Women should avoid pregnancy for
         <strong>
          three years
         </strong>
         after discontinuing acitretin and for
         <strong>
          one month
         </strong>
         after discontinuation of isotretinoin or alitretinoin. Isotretinoin or alitretinoin are thus preferred to acitretin for women of childbearing age who have severe Darier disease. Oral retinoids should never be combined with systemic
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or tetracyclines. (See
         <a class="medical medical_review" href="/z/d/html/38.html" rel="external">
          "Oral isotretinoin therapy for acne vulgaris", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         For patients with localized hypertrophic lesions that do not respond to oral retinoids, surgical excision, laser ablation, or photodynamic therapy are therapeutic options. However, these approaches are associated with pain and/or scarring, and their long-term benefits are uncertain. (See
         <a class="local">
          'Surgical or destructive therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2858227999">
         <span class="h2">
          Treatment of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malodor due to microbial or fungal colonization or secondary infection is generally treated with topical antibiotics or antifungals (eg,
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         2% cream,
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         0.1% cream,
         <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">
          fusidic acid
         </a>
         2% cream, or
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% cream). Antibacterial washes, such as
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         gluconate 4% wash, may be used as an adjunct to topical antibiotics. Patients with extensive cutaneous infection that does not respond to topical treatment may require systemic treatment with oral antibiotics or antifungals guided by culture results.
        </p>
        <p>
         Patients with eczema herpeticum are treated with oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8287.html" rel="external">
          "Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults", section on 'Cutaneous disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H478577952">
         <span class="h1">
          GENETIC COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with Darier disease, offering referral for genetics services to discuss inheritance pattern, recurrence risk, and the pros and cons of genetic testing is appropriate. Because Darier disease is an autosomal dominant disorder, an affected person will have up to a one in two chance of having a child who is also affected.
        </p>
        <p class="headingAnchor" id="H7872176">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Darier disease have a normal life expectancy, although their quality of life may be significantly impaired. The disease follows a chronic course, and relapse is common when treatment is stopped.
        </p>
        <p class="headingAnchor" id="H58288266">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Darier disease, also known as dyskeratosis follicularis, is a rare autosomal dominant genodermatosis caused by mutations in the
         <em>
          ATP2A2
         </em>
         gene on 12q23-24.1, which encodes a sarcoplasmic/endoplasmic reticulum calcium pump (SERCA2), resulting in acantholysis and keratinocyte apoptosis. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – The initial lesions of Darier disease appear during the teenage years as skin-colored or yellow-brown, keratotic papules that involve the face, chest, back, and, less frequently, the flexural areas  (
         <a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188" href="/z/d/graphic/70000.html" rel="external">
          picture 2A-E
         </a>
         ). Nail changes, including red and white longitudinal bands with a V-shaped nick at the free margin of the nail, are frequent and characteristic  (
         <a class="graphic graphic_picture graphicRef81865" href="/z/d/graphic/81865.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Clinical variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of keratotic papules involving the seborrheic areas. A skin biopsy is needed to confirm the diagnosis. Acantholysis and dyskeratosis are the histologic hallmarks of Darier disease  (
         <a class="graphic graphic_picture graphicRef86189" href="/z/d/graphic/86189.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild or localized disease
         </strong>
         – For patients with mild disease, we suggest regular use of emollients and intermittent use of medium-potency topical corticosteroids (groups 4 and 5  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )), in addition to general skin care measures, as first-line therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with limited disease that is not controlled by emollients and topical corticosteroids, we suggest topical retinoids, such as tretinoin 0.05% cream,
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         0.1% cream, or
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         0.05% cream (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical retinoids are applied once a day for three months. (See
         <a class="local">
          'General measures'
         </a>
         above and
         <a class="local">
          'Patients with mild or localized disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe or extensive disease
         </strong>
         – We suggest oral retinoids such as
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         for patients with severe or extensive Darier disease (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Acitretin or isotretinoin is given at a dose of 0.5 mg/kg per day for three to four months, and alitretinoin is given at a dose of 10 or 30 mg per day. (See
         <a class="local">
          'Patients with severe or generalized disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1310525708">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Pui-Yan Kwok, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Darier FJ. De la psorospermose folliculaire végétante. Annales de dermatologie et de syphilographie 1889; 10:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper SM, Burge SM. Darier's disease: epidemiology, pathophysiology, and management. Am J Clin Dermatol 2003; 4:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godic A, Miljkovic J, Kansky A, Vidmar G. Epidemiology of Darier's Disease in Slovenia. Acta Dermatovenerol Alp Pannonica Adriat 2005; 14:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro CS. The phenotype of Darier's disease: penetrance and expressivity in adults and children. Br J Dermatol 1992; 127:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavadia S, Mortimer E, Munro CS. Genetic epidemiology of Darier's disease: a population study in the west of Scotland. Br J Dermatol 2002; 146:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh BK, Ang P, Goh CL. Darier's disease in Singapore. Br J Dermatol 2005; 152:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakuntabhai A, Ruiz-Perez V, Carter S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyauchi Y, Daiho T, Yamasaki K, et al. Comprehensive analysis of expression and function of 51 sarco(endo)plasmic reticulum Ca2+-ATPase mutants associated with Darier disease. J Biol Chem 2006; 281:22882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhitavat J, Fairclough RJ, Hovnanian A, Burge SM. Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey disease. Br J Dermatol 2004; 150:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhitavat J, Cobbold C, Leslie N, et al. Impaired trafficking of the desmoplakins in cultured Darier's disease keratinocytes. J Invest Dermatol 2003; 121:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leinonen PT, Hägg PM, Peltonen S, et al. Reevaluation of the normal epidermal calcium gradient, and analysis of calcium levels and ATP receptors in Hailey-Hailey and Darier epidermis. J Invest Dermatol 2009; 129:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savignac M, Simon M, Edir A, et al. SERCA2 dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat. J Invest Dermatol 2014; 134:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009; 1:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Bruce AT, Tu C, et al. Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes. J Cell Sci 2011; 124:3568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foggia L, Aronchik I, Aberg K, et al. Activity of the hSPCA1 Golgi Ca2+ pump is essential for Ca2+-mediated Ca2+ response and cell viability in Darier disease. J Cell Sci 2006; 119:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savignac M, Edir A, Simon M, Hovnanian A. Darier disease : a disease model of impaired calcium homeostasis in the skin. Biochim Biophys Acta 2011; 1813:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli A, Mackenzie DS, Zhai Y, et al. SERCA2-controlled Ca²+-dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease. J Invest Dermatol 2012; 132:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hobbs RP, Amargo EV, Somasundaram A, et al. The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKC&amp;alpha; signaling. FASEB J 2011; 25:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green EK, Gordon-Smith K, Burge SM, et al. Novel ATP2A2 mutations in a large sample of individuals with Darier disease. J Dermatol 2013; 40:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nellen RG, Steijlen PM, van Steensel MA, et al. Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease. Hum Mutat 2017; 38:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bchetnia M, Charfeddine C, Kassar S, et al. Clinical and mutational heterogeneity of Darier disease in Tunisian families. Arch Dermatol 2009; 145:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhitavat J, Macfarlane S, Dode L, et al. Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2: evidence that it is allelic to Darier's disease. J Invest Dermatol 2003; 120:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergman R, Sezin T, Indelman M, et al. Acrokeratosis verruciformis of Hopf showing P602L mutation in ATP2A2 and overlapping histopathological features with Darier disease. Am J Dermatopathol 2012; 34:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk DR, Taube JM, Bruckner AL, Lane AT. A sporadic patient with acrokeratosis verruciformis of Hopf and a novel ATP2A2 mutation. Br J Dermatol 2010; 163:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronan A, Ingrey A, Murray N, Chee P. Recurrent ATP2A2 p.(Pro602Leu) mutation differentiates Acrokeratosis verruciformis of Hopf from the allelic condition Darier disease. Am J Med Genet A 2017; 173:1975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon-Smith K, Green E, Grozeva D, et al. Genotype-phenotype correlations in Darier disease: A focus on the neuropsychiatric phenotype. Am J Med Genet B Neuropsychiatr Genet 2018; 177:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Perez VL, Carter SA, Healy E, et al. ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class. Hum Mol Genet 1999; 8:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burge S. Darier's disease--the clinical features and pathogenesis. Clin Exp Dermatol 1994; 19:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macleod RI, Munro CS. The incidence and distribution of oral lesions in patients with Darier's disease. Br Dent J 1991; 171:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suárez-Peñaranda JM, Antúnez JR, Del Rio E, et al. Vaginal involvement in a woman with Darier's disease: a case report. Acta Cytol 2005; 49:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vieites B, Seijo-Ríos S, Suárez-Peñaranda JM, et al. Darier's disease with esophageal involvement. Scand J Gastroenterol 2008; 43:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salopek TG, Krol A, Jimbow K. Case report of Darier disease localized to the vulva in a 5-year-old girl. Pediatr Dermatol 1993; 10:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernabé DG, Kawata LT, Beneti IM, et al. Multiple white papules in the palate: oral manifestation of Darier's disease. Clin Exp Dermatol 2009; 34:e270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammad H, Adler E, Yeshurun A, et al. Ophthalmic Assessment in Patients With Darier Disease. Am J Ophthalmol 2021; 227:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telfer NR, Burge SM, Ryan TJ. Vesiculo-bullous Darier's disease. Br J Dermatol 1990; 122:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Cestari R, Rebora A. Verrucous and malodorous vegetations on the legs. Darier's disease, cornifying type. Arch Dermatol 1992; 128:399, 402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foresman PL, Goldsmith LA, Ginn L, Beck AL. Hemorrhagic Darier's disease. Arch Dermatol 1993; 129:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           JONES WN, NIX TE Jr, CLARK WH Jr. HEMORRHAGIC DARIER'S DISEASE. Arch Dermatol 1964; 89:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meziane M, Chraibi R, Kihel N, et al. Linear Darier disease. Dermatol Online J 2008; 14:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakuntabhai A, Dhitavat J, Burge S, Hovnanian A. Mosaicism for ATP2A2 mutations causes segmental Darier's disease. J Invest Dermatol 2000; 115:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fölster-Holst R, Nellen RG, Jensen JM, et al. Molecular genetic support for the rule of dichotomy in type 2 segmental Darier disease. Br J Dermatol 2012; 166:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flores-Terry MÁ, García-Arpa M, Llamas-Velasco M, et al. Acral Hemorrhagic Darier Disease. Actas Dermosifiliogr 2017; 108:e49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vender R, Vender R. Acral Hemorrhagic Darier's Disease: A Case Report. J Cutan Med Surg 2016; 20:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jörg B, Erhard H, Rütten A. [A hemorrhagic acral form of dyskeratosis follicularis Darier]. Hautarzt 2000; 51:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harman M, Durdu M, İbiloğlu I. Acrokeratosis verruciformis of Hopf exhibiting Darier disease-like cytological features. Clin Exp Dermatol 2016; 41:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon-Smith K, Jones LA, Burge SM, et al. The neuropsychiatric phenotype in Darier disease. Br J Dermatol 2010; 163:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodiuk-Gad R, Lerner M, Breznitz Z, et al. Learning disabilities in Darier's disease patients. J Eur Acad Dermatol Venereol 2014; 28:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curman P, Bern J, Sand L, et al. Patients with Darier Disease Exhibit Cognitive Impairment while Patients with Hailey-Hailey Disease Do Not: An Experimental, Matched Case-control Study. Acta Derm Venereol 2021; 101:adv00476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen NJ, Lyons I, Hoogendoorn B, et al. ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes. Hum Mol Genet 1999; 8:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green E, Elvidge G, Jacobsen N, et al. Localization of bipolar susceptibility locus by molecular genetic analysis of the chromosome 12q23-q24 region in two pedigrees with bipolar disorder and Darier's disease. Am J Psychiatry 2005; 162:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cederlöf M, Bergen SE, Långström N, et al. The association between Darier disease, bipolar disorder, and schizophrenia revisited: a population-based family study. Bipolar Disord 2015; 17:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cederlöf M, Karlsson R, Larsson H, et al. Intellectual disability and cognitive ability in Darier disease: Swedish nation-wide study. Br J Dermatol 2015; 173:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Kazuno AA, Nakajima K, et al. Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey. Psychiatry Clin Neurosci 2016; 70:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cederlöf M, Curman P, Ahanian T, et al. Darier disease is associated with type 1 diabetes: Findings from a population-based cohort study. J Am Acad Dermatol 2019; 81:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachar-Wikström E, Wikström JD. Darier Disease - A Multi-organ Condition? Acta Derm Venereol 2021; 101:adv00430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayuzumi N, Ikeda S, Kawada H, et al. Effects of ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1. Br J Dermatol 2005; 152:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrt U, Brieger P. Comorbidity of keratosis follicularis (Darier's Disease) and bipolar affective disorder: an indication for valproate instead of lithium. Gen Hosp Psychiatry 2000; 22:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nath AK, Udayashankar C. Diltiazem worsens Darier's disease. Int J Dermatol 2014; 53:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagna J, Clerc C, Dupond AS. Exacerbation of Darier disease by peg-interferon beta-1a in a patient suffering from multiple sclerosis. Int J Dermatol 2018; 57:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada E, Nagai Y, Motegi S, et al. Fatal case of Darier's disease with recurrent severe infections. Acta Derm Venereol 2009; 89:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo SM, Won CH, Cho S. Darier's disease: variable clinical presentation and a fatal outcome. Clin Exp Dermatol 2009; 34:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haase O, Moser A, Rose C, et al. Generalized cowpox infection in a patient with Darier disease. Br J Dermatol 2011; 164:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogt KA, Lohse CM, El-Azhary RA, et al. Kaposi varicelliform eruption in patients with Darier disease: a 20-year retrospective study. J Am Acad Dermatol 2015; 72:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czyz C, Sharma P, Grossniklaus HE, et al. Clinical and pathologic eyelid alterations in a patient with Darier disease. Ophthalmic Plast Reconstr Surg 2011; 27:e170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlsson AM, Barrett GD. Postoperative endophthalmitis in a patient with Darier-White disease. Can J Ophthalmol 2007; 42:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mielke J, Grüb M, Besch D, Schlote T. Recurrent corneal ulcerations with perforation in keratosis follicularis (Darier-White disease). Br J Ophthalmol 2002; 86:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radia M, Gilhooley MJ, Panos C, Claoué C. Recurrent presumed herpes simplex keratitis and episcleritis in keratosis follicularis (Darier's disease). BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008; 159:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui K, Makino T, Nakano H, et al. Squamous cell carcinoma arising from Darier's disease. Clin Exp Dermatol 2009; 34:e1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogan S, Karaduman A, Erkin G, Gokoz O. Effective treatment of linear Darier's disease with topical retinoids: case report and review of the literature. Acta Dermatovenerol Croat 2011; 19:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casals M, Campoy A, Aspiolea F, et al. Successful treatment of linear Darier's disease with topical adapalene. J Eur Acad Dermatol Venereol 2009; 23:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998; 38:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubegni P, Poggiali S, Sbano P, et al. A case of Darier's disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol 2006; 20:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Carmona L, Fleta-Asín B, Moreno-García-Del-Real C, Jaén-Olasolo P. Successful treatment of Darier's disease with topical pimecrolimus. Eur J Dermatol 2011; 21:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe M, Yasuda M, Yokoyama Y, Ishikawa O. Successful treatment of combination therapy with tacalcitol lotion associated with sunscreen for localized Darier's disease. J Dermatol 2010; 37:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millán-Parrilla F, Rodrigo-Nicolás B, Molés-Poveda P, et al. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol 2014; 70:e89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soenen A, Saint-Jean M, Daguzé J, et al. Combination of alitretinoin and topical 5-fluorouracil in Darier disease. JAAD Case Rep 2019; 5:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farb RM, Lazarus GS, Chiaramonti A, et al. The effect of 13-cis retinoic acid on epidermal lysosomal hydrolase activity in Darier's disease and pityriasis rubra pilaris. J Invest Dermatol 1980; 75:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Aoki M, Kawana S. Localized Darier's disease of the scalp: successful treatment with oral etretinate. Dermatology 2004; 208:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christophersen J, Geiger JM, Danneskiold-Samsoe P, et al. A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease. Acta Derm Venereol 1992; 72:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letulé V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol 2013; 38:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anuset D, Goutorbe C, Bernard P, Reguiai Z. Efficacy of oral alitretinoin for the treatment of Darier disease: a case report. J Am Acad Dermatol 2014; 71:e46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestri R, Patrizi A, Bardazzi F. Alitretinoin and Darier disease: "All that glisters is not gold". J Am Acad Dermatol 2015; 72:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boehmer D, Eyerich K, Darsow U, et al. Variable response to low-dose naltrexone in patients with Darier disease: a case series. J Eur Acad Dermatol Venereol 2019; 33:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legrand A, Darrigade AS, Taieb A, et al. Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease. JAAD Case Rep 2020; 6:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeland RG, Gilmore WA. The surgical treatment of hypertrophic Darier's disease. J Dermatol Surg Oncol 1985; 11:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toombs EL, Peck GL. Electrosurgical treatment of etretinate-resistant Darier's disease. J Dermatol Surg Oncol 1989; 15:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahcan U, Dolenc-Voljc M, Zivec K, et al. The surgical treatment of hypertrophic intertriginous Darier's disease. J Plast Reconstr Aesthet Surg 2009; 62:e442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown VL, Kelly SE, Burge SM, Walker NP. Extensive recalcitrant Darier disease successfully treated with laser ablation. Br J Dermatol 2010; 162:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol 1990; 23:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minsue Chen T, Wanitphakdeedecha R, Nguyen TH. Carbon dioxide laser ablation and adjunctive destruction for Darier-White disease (keratosis follicularis). Dermatol Surg 2008; 34:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beier C, Kaufmann R. Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease. Arch Dermatol 1999; 135:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roos S, Karsai S, Ockenfel HM, Raulin C. Successful treatment of Darier disease with the flashlamp-pumped pulsed-dye laser. Arch Dermatol 2008; 144:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz TM, Firoz BF, Goldberg LH, Friedman PM. Treatment of Darier's disease using a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2010; 36:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 2003; 149:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avery HL, Hughes BR, Coley C, Cooper HL. Clinical improvement in Darier's disease with photodynamic therapy. Australas J Dermatol 2010; 51:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung N, Cardones AR, Larrier N. Long-term improvement of recalcitrant Darier disease with photon and electron beam radiation therapy. JAAD Case Rep 2018; 4:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ossorio-García L, Collantes-Rodríguez C, Villegas-Romero I, Linares-Barrios M. Vegetating Darier Disease Treated With Botulinum Toxin. JAMA Dermatol 2018; 154:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulf HC, Wiegell SR. Dyskeratosis follicularis cured by superficial radiotherapy: long-term follow-up of 10 patients. J Eur Acad Dermatol Venereol 2021; 35:e230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350:1143.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15462 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : De la psorospermose folliculaire végétante
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12553850" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Darier's disease: epidemiology, pathophysiology, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16001099" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiology of Darier's Disease in Slovenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1390140" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The phenotype of Darier's disease: penetrance and expressivity in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11841374" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic epidemiology of Darier's disease: a population study in the west of Scotland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15727640" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Darier's disease in Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080178" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16766529" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comprehensive analysis of expression and function of 51 sarco(endo)plasmic reticulum Ca2+-ATPase mutants associated with Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15149492" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14675181" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Impaired trafficking of the desmoplakins in cultured Darier's disease keratinocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19052563" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reevaluation of the normal epidermal calcium gradient, and analysis of calcium levels and ATP receptors in Hailey-Hailey and Darier epidermis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24390139" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : SERCA2 dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20049730" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22045735" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467572" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Activity of the hSPCA1 Golgi Ca2+ pump is essential for Ca2+-mediated Ca2+ response and cell viability in Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21167218" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Darier disease : a disease model of impaired calcium homeostasis in the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22277942" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : SERCA2-controlled Ca²+-dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21156808" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKC&amp;alpha; signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23356892" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Novel ATP2A2 mutations in a large sample of individuals with Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28035777" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19528419" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical and mutational heterogeneity of Darier disease in Tunisian families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12542527" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2: evidence that it is allelic to Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22814319" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acrokeratosis verruciformis of Hopf showing P602L mutation in ATP2A2 and overlapping histopathological features with Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20518781" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A sporadic patient with acrokeratosis verruciformis of Hopf and a novel ATP2A2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28498512" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Recurrent ATP2A2 p.(Pro602Leu) mutation differentiates Acrokeratosis verruciformis of Hopf from the allelic condition Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30345710" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Genotype-phenotype correlations in Darier disease: A focus on the neuropsychiatric phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10441324" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1619075" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Darier-White disease: a review of the clinical features in 163 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8033376" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Darier's disease--the clinical features and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1931295" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The incidence and distribution of oral lesions in patients with Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16334031" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Vaginal involvement in a woman with Darier's disease: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19086284" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Darier's disease with esophageal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8346108" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Case report of Darier disease localized to the vulva in a 5-year-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438571" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Multiple white papules in the palate: oral manifestation of Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33737033" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ophthalmic Assessment in Patients With Darier Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369561" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vesiculo-bullous Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550378" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Verrucous and malodorous vegetations on the legs. Darier's disease, cornifying type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466227" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hemorrhagic Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14107616" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : HEMORRHAGIC DARIER'S DISEASE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19265624" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Linear Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11121153" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mosaicism for ATP2A2 mutations causes segmental Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21895618" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Molecular genetic support for the rule of dichotomy in type 2 segmental Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28407871" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acral Hemorrhagic Darier Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26992421" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Acral Hemorrhagic Darier's Disease: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11116851" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : [A hemorrhagic acral form of dyskeratosis follicularis Darier].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27663152" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acrokeratosis verruciformis of Hopf exhibiting Darier disease-like cytological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20456342" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The neuropsychiatric phenotype in Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23410204" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Learning disabilities in Darier's disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33928397" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Patients with Darier Disease Exhibit Cognitive Impairment while Patients with Hailey-Hailey Disease Do Not: An Experimental, Matched Case-control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10441325" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625199" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Localization of bipolar susceptibility locus by molecular genetic analysis of the chromosome 12q23-q24 region in two pedigrees with bipolar disorder and Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25213221" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The association between Darier disease, bipolar disorder, and schizophrenia revisited: a population-based family study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25704118" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Intellectual disability and cognitive ability in Darier disease: Swedish nation-wide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27106560" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31163229" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Darier disease is associated with type 1 diabetes: Findings from a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33606037" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Darier Disease - A Multi-organ Condition?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840101" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10896494" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comorbidity of keratosis follicularis (Darier's Disease) and bipolar affective disorder: an indication for valproate instead of lithium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24261918" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Diltiazem worsens Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29076157" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Exacerbation of Darier disease by peg-interferon beta-1a in a patient suffering from multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19688156" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Fatal case of Darier's disease with recurrent severe infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19236417" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Darier's disease: variable clinical presentation and a fatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21275935" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Generalized cowpox infection in a patient with Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25582540" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Kaposi varicelliform eruption in patients with Darier disease: a 20-year retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21326126" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical and pathologic eyelid alterations in a patient with Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361258" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Postoperative endophthalmitis in a patient with Darier-White disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12234910" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recurrent corneal ulcerations with perforation in keratosis follicularis (Darier-White disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26184361" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Recurrent presumed herpes simplex keratitis and episcleritis in keratosis follicularis (Darier's disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18489606" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20055824" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Squamous cell carcinoma arising from Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21933650" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effective treatment of linear Darier's disease with topical retinoids: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18624851" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Successful treatment of linear Darier's disease with topical adapalene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632016" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Tazarotene gel for Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16405615" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A case of Darier's disease successfully treated with topical tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21489907" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Successful treatment of Darier's disease with topical pimecrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20649714" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Successful treatment of combination therapy with tacalcitol lotion associated with sunscreen for localized Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24629373" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Improvement of Darier disease with diclofenac sodium 3% gel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30581938" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Combination of alitretinoin and topical 5-fluorouracil in Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6997395" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The effect of 13-cis retinoic acid on epidermal lysosomal hydrolase activity in Darier's disease and pityriasis rubra pilaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14730246" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Localized Darier's disease of the scalp: successful treatment with oral etretinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1350407" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23777494" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treatment of Darier disease with oral alitretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25037810" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of oral alitretinoin for the treatment of Darier disease: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592350" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Alitretinoin and Darier disease: "All that glisters is not gold".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30712317" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Variable response to low-dose naltrexone in patients with Darier disease: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32149174" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3980841" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The surgical treatment of hypertrophic Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2592667" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Electrosurgical treatment of etretinate-resistant Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955026" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The surgical treatment of hypertrophic intertriginous Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19912213" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Extensive recalcitrant Darier disease successfully treated with laser ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2123894" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18657162" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Carbon dioxide laser ablation and adjunctive destruction for Darier-White disease (keratosis follicularis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10206049" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18711096" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Successful treatment of Darier disease with the flashlamp-pumped pulsed-dye laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19912279" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Treatment of Darier's disease using a 1,550-nm erbium-doped fiber laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14510996" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of Darier's disease with photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20148839" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clinical improvement in Darier's disease with photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30510999" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Long-term improvement of recalcitrant Darier disease with photon and electron beam radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29141083" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Vegetating Darier Disease Treated With Botulinum Toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32977367" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Dyskeratosis follicularis cured by superficial radiotherapy: long-term follow-up of 10 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15940677" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9343507" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Safety of first-trimester exposure to topical tretinoin: prospective cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
